PI
NKGN

PEAK6 Investments’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

PEAK6 Investments’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55,195
Closed -$559K – 4836
2023
Q1 		$559K Hold
55,195
– – ﹤0.01% 2302
2022
Q4 		$549K Hold
55,195
– – ﹤0.01% 2428
2022
Q3 		$538K Hold
55,195
– – ﹤0.01% 2796
2022
Q2 		$536K Buy
+55,195
New +$537K ﹤0.01% 3747

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

PEAK6 Investments's NKGN Position: Q2 2023 in Review

PEAK6 Investments sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 55,195 shares — an estimated $559K sold.

PEAK6 Investments first reported a position in NKGN in Q2 2022 and held it in 4 quarters. The position peaked at $559K in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • PEAK6 Investments reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PEAK6 Investments sold 55,195 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $559K.
  • PEAK6 Investments first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • PEAK6 Investments's NKGen Biotech, Inc. Common Stock position peaked at $559K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.